US
Updated
Reviewed by Vidhi Upadhyay
US Cardiac Biomarker Testing Market Industry Trends and Forecast to 2034: Segmented by (Biomarker, Setting, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
US · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
US (this report) at $2.93 Bn.
Canada at 7.1% a year.Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$1.54 Bn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $2.79 Bn | — | — |
| 2025 (base) | $2.93 Bn | +$134.2 Mn | — |
| 2026 (forecast) | $3.07 Bn | +$140.6 Mn | +4.8% |
| 2027 (forecast) | $3.22 Bn | +$147.3 Mn | +9.8% |
| 2028 (forecast) | $3.37 Bn | +$154.4 Mn | +15.1% |
| 2029 (forecast) | $3.53 Bn | +$161.8 Mn | +20.6% |
| 2030 (forecast) | $3.70 Bn | +$169.6 Mn | +26.4% |
| 2031 (forecast) | $3.88 Bn | +$177.7 Mn | +32.5% |
| 2032 (forecast) | $4.07 Bn | +$186.3 Mn | +38.8% |
| 2033 (forecast) | $4.26 Bn | +$195.2 Mn | +45.5% |
| 2034 (forecast) | $4.47 Bn | +$204.6 Mn | +52.5% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
US (this report)
$2.93 Bn
China
$639.4 Mn
Canada
$508.1 Mn
Japan
$505.0 Mn
Germany
$245.7 Mn
France
$223.6 Mn
Italy
$203.0 Mn
Brazil
$195.7 Mn
UK
$170.6 Mn
Ecuador
$156.6 Mn
India
$162.7 Mn
Spain
$149.6 Mn
Mexico
$115.9 Mn
Saudi Arabia
$113.6 Mn
Australia
$103.0 Mn
New Zealand
$84.5 Mn
Russia
$73.6 Mn
South Africa
$53.8 Mn
UAE
$38.8 Mn
Egypt
$21.2 Mn
Philippines
$19.2 Mn
Malaysia
$13.8 Mn
Hong Kong
$12.6 Mn
Thailand
$8.8 Mn
Singapore
$8.7 Mn
Kenya
$6.0 Mn
| Market size, 2025 | $2.93 Bn placeholder estimate |
|---|---|
| Forecast, 2034 | $4.47 Bn placeholder estimate |
| Growth (CAGR), 2025–2034 | 4.8% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Also called | Cardiac Marker Testing |
| Segments | Biomarker, setting and end user (see all) |
| Key players | Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Beckman Coulter (Danaher), Quidel Corporation (see all) |
| Regulator in the US | FDASource: US Food and Drug Administration. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Cardiac biomarker tests measure proteins such as troponin and BNP in blood to diagnose heart attacks and heart failure.
Key segments of the cardiac Biomarker Testing market include biomarker (Troponin, BNP and NT-proBNP and CK-MB) and setting (Central Labs and Point of Care).
Demand for earlier and faster diagnosis, growth of testing outside hospitals, new molecular technologies and the shift to preventive care are driving the cardiac Biomarker Testing market.
Home testing, connected devices that send results to doctors and multiplex tests that check many conditions at once give the cardiac Biomarker Testing market room to grow, especially in emerging markets.
Pricing pressure, uneven reimbursement for new tests, regulatory approval times and the need for skilled lab staff hold back the cardiac Biomarker Testing market.
The cardiac Biomarker Testing market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
The FDA clears or approves medical devices by risk class, through 510(k) clearance, De Novo classification or premarket approval (PMA).[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).[2]
[1] US Food and Drug Administration. Checked 14 Nov 2026.
[2] Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how cardiac Biomarker Testing products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in US.
What doctors and scientists are doing in Cardiac Biomarker Testing right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.
From our blog
US · 1 shared keyword
US · 1 shared keyword
US · 1 shared keyword
US · 1 shared keyword
US
US
Digital Health · US
Digital Health · US
Healthcare Services · US
Pharmaceuticals · US
Pharmaceuticals · US
Healthcare Services · US